Take­da part­ners with an up­start drugs-from-bugs mi­cro­bio­me play­er in­spired by a fe­cal trans­plan­ta­tion biz

Back when Mark Smith was work­ing on his PhD at MIT about 6 years ago, his girl­friend’s cousin was in­fect­ed with C.diff. Af­ter 7 re­oc­cur­rences fol­low­ing treat­ment with van­comycin, though, the cousin fi­nal­ly beat it by get­ting a fe­cal trans­plant, with his room­mate as the donor.

That in­ci­dent both in­trigued him and in­spired Smith’s first jump in­to a start­up, Open­Bio­me, which us­es screened fe­cal sam­ples for a more sys­tem­at­ic ap­proach in cre­at­ing a safe, re­li­able sup­ply of trans­plants to a grow­ing mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.